



CONGRESS 2024  
SANTIAGO - CHILE 

SEPTEMBER 9<sup>th</sup>-11<sup>th</sup>

# Scientific Program

[www.congresoaleh.com](http://www.congresoaleh.com)



09:00–11:00		ROOM A POSTGRADUATE COURSE Complications of liver cirrhosis MODERATORS Juanita Pérez, MD (MEXICO) - Gabriel Mezzano, MD (CHILE)
09:00–09:10	<b>Welcome to the postgraduate course</b> Graciela Castro, MD (MEXICO) · Javier Brahm, MD (CHILE)	
09:10–09:25	<b>Current prevalence of chronic liver disease</b> Jeffrey Lazarus, MD (SPAIN)	
09:25–09:40	<b>New concepts on the stratification of compensated and decompensated cirrhosis according Baveno VII</b> Brett Fortune, MD (USA)	
09:40–09:55	<b>Hepatic encephalopathy: old and new approaches</b> Grace L. Su, MD (USA) 	
09:55–10:10	<b>Treatment of acute kidney injury-Hepatorenal Syndrome</b> Aldo Torre, MD (MEXICO)	
10:10–10:25	<b>Refractory ascites: TIPS vs medical treatment</b> Virginia Hernández, MD (SPAIN)	
10:25–10:40	<b>Treatment of bacterial infections in patients with cirrhosis</b> Sebastián Marciano, MD (ARGENTINA)	
10:40–11:00	<b>Q&amp;A</b> Juanita Pérez, MD (MEXICO) - Gabriel Mezzano, MD (CHILE)	
11:00–11:30		COFFEE BREAK
11:30–13:00		MODERATORS Marco Arrese, MD (CHILE) · José Antonio Velarde, MD (MEXICO)
11:30–11:45	<b>Antibiotic prophylaxis for spontaneous bacterial peritonitis: benefit or risk?</b> Angelo Mattos, MD (BRAZIL)	
11:45–12:00	<b>Sarcopenia and frailty: a predictor of poor prognosis in liver cirrhosis</b> Carlos Benítez, MD (CHILE)	
12:00–12:15	<b>Comprehensive management in ACLF</b> Mario Reis, MD (BRAZIL)	
12:15–12:30	<b>Endoscopic tools in the hands of the hepatologist: Endohepatology</b> Iván López-Méndez, MD (MEXICO)	
12:30–13:00	<b>Q&amp;A</b> Marco Arrese, MD (CHILE) · José Antonio Velarde, MD (MEXICO)	
13:00–14:00	<b>ROOM A CELLPHARMA SYMPOSIUM</b> Liver fibrosis: a dynamic reversible process	<b>ROOM EUROPA MERZ SYMPOSIUM</b> Role of L-Ornithine-L-Aspartate (LOLA) in Hepatic Encephalopathy. New evidence in the recent LATAM Consensus and beyond.

14:30–15:45		<b>MODERADORES</b> Dr. Fernando Bessone (ARGENTINA) • Dra. Eira Cerda (MÉXICO)
14:30–14:45	<b>Practical considerations in volume management in cirrhosis patients</b> Elliot Tapper, MD (USA)	
14:45–15:00	<b>Transplant in ACLF, are there any contraindications?</b> George Therapondos, MD (USA)	
15:00–15:15	<b>Downstaging in transplantation and post immunotherapy reconversion therapy concept</b> Federico Piñero, MD (ARGENTINA)	
15:15–15:30	<b>Palliative care in end-stage liver disease</b> José Presa, MD (PORTUGAL)	
15:30–15:45	<b>Q&amp;A</b> Fernando Bessone, MD (ARGENTINA) • Eira Cerda, MD (MEXICO)	
15:45–16:15		<b>BREAK</b>
16:15–17:50		<b>SALÓN A</b> <b>Joint Session ALEH-EASL: Steatotic Liver Disease (SLD)</b> MODERATORS Mario Pessoa, MD (BRAZIL) • Graciela Castro, MD (MEXICO)
16:15–16:30	<b>Implementation of the new nomenclature</b> Francesco P. Russo, MD (ITALY)	
16:30–16:45	<b>The role of alcohol in SLD</b> Aleksander Krag, MD (DENMARK)	
16:45–17:00	<b>Targeting the gut microbiome to treat SLD</b> *Virtual Conference Debbie Shawcross, MD (ENGLAND)	
17:00–17:15	<b>Steatotic Liver Disease, MASLD and risk of chronic kidney disease</b> Marcelo Silva, MD (ARGENTINA)	
17:15–17:30	<b>Q&amp;A</b> Mario Pessoa, MD (BRAZIL) • Graciela Castro, MD (MEXICO)	
17:30–17:50	<b>Closing of the postgraduate course</b> Graciela Castro, M.D. (MEXICO)	

14:00–18:00

**ROOM ANTARTICA**

**Artificial Intelligence Workshop**

Juan Turnes, MD (SPAIN) • Manuel Mendizabal, MD (ARGENTINA)

07:00–08:30	<b>ROOM ANTARTICA</b> Coffee with Experts Sebastián Marciano, MD (ARGENTINA) • Angelo Mattos, MD (BRAZIL)	
08:30–10:00	<b>ROOM A</b> <b>AASLD-ALEH-APASL-EASL GLOBAL LIVER FORUM   TOPIC Hepatitis B</b> MODERATORS Graciela Castro, MD (MEXICO) • Nelia Hernández, MD (URUGUAY)	09:00–15:50 <b>ROOM EUROPA</b> Young Investigators Workshop AASLD
08:30–08:45	<b>Should we treat patients in the Immunetolerant phase?</b> Mario Pessoa, MD (BRAZIL)	
08:45–09:00	<b>Can we stop nucleotide analogues in HBeAg negative patients?</b> Francesco P. Russo, MD (ITALY) ⓘ	
09:00–09:15	<b>From Chronic Hepatitis B to Hepatocellular Carcinoma. Who are the main players?</b> W. Ray Kim, MD (USA) ⓘ	
09:15–09:30	<b>New treatments for Chronic Hepatitis B</b> Lai Wei, MD (CHINA) ⓘ	
09:30–10:00	<b>Q&amp;A</b> Graciela Castro, MD (MEXICO) • Nelia Hernández, MD (URUGUAY)	
10:00–11:00	<b>COFFEE BREAK / POSTERS</b>	
11:00–12:30	<b>ROOM A</b> <b>MASLD I</b> MODERATORS Fátima Higuera, MD (MEXICO) • Lorena Castro, MD (CHILE)	<b>ROOM B</b> <b>Liver damage related alcohol consumption I</b> MODERATORS José Luis Pérez, MD (MEXICO) • Enrique Carrera, MD (ECUADOR)
11:00–11:15	<b>MASLD and risk of Hepatocellular Carcinoma</b> Claudia D. Oliveira, MD (BRAZIL)	<b>Molecular basis of alcohol withdrawal and relapse in alcohol-related liver disease</b> Juan Pablo Roblero, MD (CHILE)
11:15–11:25	<b>0-1</b> Long-term efficacy and safety of open-label Seladelpar treatment in patients with Primary Biliary Cholangitis: interim 2-year results from the assure study Alejandra Villamil, MD (ARGENTINA)	<b>0-2</b> Wilson Disease (WD) diagnosis with next-generation sequencing (NGS) in clinical practice: a pilot study Marta Mitiko Deguti, MD (BRASIL)
11:25–11:35	<b>0-13</b> Cholangiocarcinoma in Latin America: a multicenter observational study alerts on ethnical disparities in tumor presentation and outcome Laura Izquierdo-Sánchez, MD (ESPAÑA)	<b>0-4</b> Epidemiology of Primary Biliary Cholangitis in Latin America: preliminary results from allatin cohort Claudia Alves Couto, MD (BRASIL)
11:35–11:50	<b>When to think about MetALD?</b> Elisa Pose, MD (SPAIN)	<b>Actions in Latin America on liver damage related to alcohol consumption</b> Luis Antonio Díaz, MD (CHILE)
11:50–12:00	<b>0-5</b> Acute-on-Chronic Liver Failure (ACLF) criteria in alcohol-associated hepatitis: implications for liver transplantation Paula Huerta, MD (CHILE)	<b>0-6</b> Evaluation of the hepatoprotective activity of flourensia cernua and its impact on the aerobic intestinal microbiota in a valproic acid-induced damage model in wistar rats Liliana Torres González, MD (MÉXICO)
12:00–12:10	<b>0-7</b> Further exploration of differences between lean and non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) in Latino subjects: PNPLA3 frequency and lipidomic profiles María Ayala-Valverde, MD (CHILE)	<b>0-8</b> Second line therapy in patients with Primary Biliary Cholangitis and inadequate response: are we choosing the right target population for clinicals trials? Natalia Sobenko, MD (ARGENTINA)
12:10–12:30	<b>Q&amp;A</b> Fátima Higuera, MD (MEXICO) • Lorena Castro, MD (CHILE)	<b>Q&amp;A</b> José Luis Pérez, MD (MEXICO) • Enrique Carrera, MD (ECUADOR)
13:00–14:00	<b>INTERCEPT SYMPOSIUM</b>	

ROOM A Autoimmunes Liver Disease MODERATORS Norberto Chávez, MD (MEXICO) · Leyla Nazal, MD (CHILE)		ROOM B Hepatocellular Carcinoma MODERATORS Ezequiel Ridruejo, MD (ARGENTINA) · Claudia Oliveira, MD (BRAZIL)	
14:00–15:25		14:00–14:15	<b>Combined therapies in Primary Biliary Cholangitis</b> Alejandra Villamil, MD (ARGENTINA)
14:15–14:25	<b>0-9</b> Assessing the burden and budget impacts of HCV elimination strategies in Uruguay using decision-analytic modeling Victoria Mainardi, MD (URUGUAY)	14:15–14:25	<b>0-10</b> Non-steroidal anti-inflammatory drugs: a comparative analysis between the spanish and LATINDILI networks Fernando Bessone, MD (ARGENTINA)
14:25–14:40	<b>Atypical Forms of Autoimmune Hepatitis</b> Álvaro Urzúa, MD (CHILE)	14:25–14:40	<b>What is the best biomarker for diagnosis, treatment and follow-up in Hepatocellular Carcinoma?</b> Josefina Pagés, MD (ARGENTINA)
14:40–14:50	<b>0-11</b> Detection strategy for patients with viral hepatitis using laboratory records of blood samples for HBsAg and HCV antibodies: PANRELINK Fernando Cairo, MD (ARGENTINA)	14:40–14:50	<b>0-12</b> Deciphering Wilson's Disease in Costa Rica: an innovative genetic approach Francisco Hevia Urrutia, MD (COSTA RICA)
14:50–15:05	<b>Standard treatment and treatment alternatives in autoimmune hepatitis</b> Claudia Couto, MD (BRAZIL)	14:50–15:05	<b>Synergizing therapies in hepatocellular carcinoma: immunotherapy and locoregional therapies</b> Federico Piñero, MD (ARGENTINA)
15:05–15:25	<b>Q&amp;A</b> Norberto Chávez, MD (MEXICO) · Leyla Nazal, MD (CHILE)	15:05–15:25	<b>Q&amp;A</b> Ezequiel Ridruejo, MD (ARGENTINA) · Claudia Oliveira, MD (BRAZIL)
15:25–16:10 COFFEE BREAK / POSTERS			
ROOM A MASLD II MODERATORS Iván López-Méndez, MD (MEXICO) · Mario Reis, MD (BRAZIL)		ROOM B Hot Topics in Hepatology MODERATORS Rosalba Moreno, MD (MEXICO) · Josefina Pages, MD (ARGENTINA)	
16:10–16:25	<b>Genetics and epigenetics in MASLD</b> Norberto Chávez, MD (MEXICO)	16:10–16:25	<b>HILI in Latin America</b> Fernando Bessone, MD (ARGENTINA)
16:25–16:40	<b>MASLD and Type 2 Diabetes: A risk relationship</b> Marco Arrese, MD (CHILE)	16:25–16:40	<b>Hepatitis C in 2024</b> Fernando Contreras, MD (DOMINICAN REPUBLIC)
16:40–16:55	<b>Cardiovascular risk in MASLD: How to prevent and treat?</b> Mónica Acevedo, MD (CHILE)	16:40–16:55	<b>Fulminant hepatitis, when to do transplant?</b> Santiago Muñoz, MD (CHILE)
16:55–17:10	<b>Non-invasive markers for the diagnosis, treatment and follow-up in MASLD</b> Adrián Gadano, MD (ARGENTINA)	16:55–17:10	<b>Immune-mediated hepatitis due to immune checkpoint inhibitors</b> Nelia Hernández, MD (URUGUAY)
17:10–17:30	<b>Q&amp;A</b> Iván López-Méndez, MD (MEXICO) · Mario Reis, MD (BRAZIL)	17:10–17:30	<b>Q&amp;A</b> Rosalba Moreno, MD (MEXICO) · Josefina Pages, MD (ARGENTINA)
17:30–18:00 <b>Master Conference Presentation</b> MODERATORS Mario Pessoa, MD (BRAZIL) · Graciela Castro, MD (MEXICO) <b>State-of-the-art Lecture</b> Update on the Global Epidemiology of MASLD and MASH Zobair Younoussi, MD (USA)			
18:00–19:15 <b>ALEH Assembly</b>			

09:00 - 15.50

# Young Investigators Workshop ALEH-AASLD

09:00–09:10	<b>Introduction</b> W. Ray Kim, MD (USA) • Manuel Mendizabal, MD (ARGENTINA)
<b>SESSION 1 - Academic Journey</b>	
09:10–09:30	<b>Pursuing an academic career: risk, rewards and milestones</b> Brett Fortune, MD (USA)
09:30–09:50	<b>Building resilience and preventing burnout for long term success</b> Grace L. Su, MD (USA)
09:50–10:10	<b>What makes a healthy mentorship</b> Brian Lee, MD (USA)
10:10–10:30	<b>How to be a good mentee</b> Marcos Arrese, MD (CHILE)
10:30–10:40	<b>Q&amp;A Panel</b>
10:40–11:00	<b>BREAK</b>
<b>SESSION 2 - Generating and disseminating data</b>	
11:00–11:20	<b>Conceiving the research questions</b> Sebastián Marciano, MD (ARGENTINA)
11:20–11:40	<b>Fundamentals of observational studies</b> W. Ray Kim, MD (USA)
11:40–12:00	<b>How to give effective presentation</b> Manuel Mendizabal, MD (ARGENTINA)
12:00–12:20	<b>Using social media to promote your science and career</b> Elliot Tapper, MD (USA)
12:20–12:30	<b>Q&amp;A Panel</b>

<b>SESSION 3 - Publication for high impact</b>	
12:30–12:50	<b>How to write a paper and get published</b> Luis Antonio Díaz, MD (CHILE)
12:50–13:10	<b>What editors look for in papers</b> Norberto Chávez-Tapia, MD (MEXICO)
13:10–14:10	<b>Networking lunch</b>
<b>SESSION 4 - Poster Session</b>	
14:10–15:40	<b>Group 1: Viral Hepatitis</b> Elliot Tapper, MD (USA) • Manuel Mendizabal, MD (ARGENTINA)
	<b>Group 2: Cirrhosis</b> Brett Fortune, MD (USA) • Luis Antonio Díaz, MD (CHILE)
	<b>Group 3: Fatty Liver</b> Sebastián Marciano, MD (ARGENTINA) • Brian Lee, MD (USA)
	<b>Group 4: HCC</b> Grace L. Su, MD (USA) • Mario Pessoa, MD (BRAZIL)
15:40–15:50	<b>Closing</b>

07:00–08:15	<b>ROOM ANTARTICA</b> Interest Groups Meeting	
08:30–10:15	<b>ROOM A</b> <b>AASLD-ALEH SYMPOSIUM</b> From liver cirrhosis to liver transplantation <small>MODERATORS</small> Brett Fortune, MD (USA) Manuel Mendizabal, MD (ARGENTINA)	<b>ROOM EUROPA</b> <b>Hepocus Workshop</b> Diego Arufe, MD (ARGENTINA) • Edgar Santino, MD (MEXICO) José Antonio Velarde, MD (MEXICO)
08:30–08:45	<b>Strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation</b> W. Ray Kim, MD (USA)	
08:45–09:00	<b>Challenges in liver transplantation in Latin America</b> Rodrigo Zapata, MD (CHILE)	
09:00–09:15	<b>Frailty and Liver Transplantation</b> Elliot Tapper, MD (USA)	
09:15–09:30	<b>Post-liver transplant immunotolerance</b> Juanita Pérez, MD (MEXICO)	
09:30–09:45	<b>Diagnosing liver cirrhosis through artificial intelligence</b> Grace L. Su, MD (USA)	
09:45–10:15	<b>Q&amp;A</b> Brett Fortune, MD (USA) • Manuel Mendizabal, MD (ARGENTINA)	
10:15–11:15	<b>COFFEE BREAK / POSTERS</b>	
11:15–13:00	<b>ROOM A</b> <b>Miscellaneous</b> <small>MODERATORS</small> Alejandro Soza, MD (CHILE) • Nicolás Fernández, MD (MEXICO)	<b>ROOM B</b> <b>Hepatology Challenges</b> <small>MODERATORS</small> Carlos Benítez, MD (CHILE) • Juan Miguel Abdo, MD (MEXICO)
11:15–11:30	<b>Living Donor Liver Transplantation: In the real world</b> George Therapondos, MD (USA)	<b>11:15-11:30</b> <b>Uncommon causes of hepatic steatosis</b> Francisco Barrera, MD (CHILE)
11:30–11:40	<b>0-3</b> <b>Assessing treatment eligibility expansion under the 2024 WHO Guidelines for Chronic Hepatitis B</b> Manuel Mendizabal, MD (ARGENTINA)	<b>11:30-11:45</b> <b>Is reversal of liver fibrosis currently possible?</b> Daniel Cabrera, MD (CHILE)
11:40–11:50	<b>0-14</b> <b>Enhanced muscle mass mitigates MALSD in myostatin knockout mice without impacting exercise performance</b> Faride Saud Zapura, MD (CHILE)	<b>11:45-12:00</b> <b>Clinical trials in primary biliary cholangitis</b> Alejandra Villamil, MD (ARGENTINA)
11:50–12:05	<b>Benign liver tumors</b> Santiago Muñoz, MD (CHILE)	
12:05–12:15	<b>0-15</b> <b>Outcome of pregnancies in a series of Wilson disease patients</b> Marta Mitiko Deguti, MD (BRASIL)	<b>12:00-12:15</b> <b>Perioperative managment of patients with advanced chronic liver disease</b> José Antonio Velarde, MD (MEXICO)
12:15–12:25	<b>0-16</b> <b>Frequency of ATP7B gene mutations in a brazilian cohort of patients with Wilson's disease</b> Vivian Rotman, MD (BRASIL)	<b>12:15-12:30</b> <b>Adrenal failure in cirrhosis</b> Jorge Garavito, MD (PERU)
12:25–12:40	<b>Noninvasive markers in alcohol liver disease</b> Aleksander Krag, MD (DENMARK)	<b>12:30-12:45</b> <b>Indications of antioxidants in liver diseases</b> José Luis Pérez, MD (MEXICO)
12:40–13:00	<b>Q&amp;A</b> Alejandro Soza, MD (CHILE) • Ezequiel Ridruejo, MD (ARGENTINA)	<b>12:45-13:00</b> <b>Q&amp;A</b> Carlos Benítez, MD (CHILE) • Juan Miguel Abdo, MD (MEXICO)
13:00–14:00	<b>ROOM A</b> GILEAD SYMPOSIUM Winds of Change in Viral Hepatitis	

14:30–15:45		ROOM A Rounds in Hepatology I MODERATORS Brian Lee, MD (USA) · Gabriel Mezzano, MD (CHILE)	ROOM B Rounds in Hepatology II MODERATORS Nicolás Fernández, MD (MEXICO) · Kriss del Rocío Rodríguez, MD (PERU)
14:30–14:50	<b>Transplantation in severe acute hepatitis related to alcohol</b> FOR: George Therapondos, MD (USA)   AGAINST: Elisa Pose, MD (SPAIN)		<b>Benefits of new MASLD nomenclature</b> Adrián Gadano, MD (ARGENTINA)
			<b>Challenges ahead in LATAM</b> Luis Antonio Díaz, MD (CHILE)
14:50–15:10	<b>Use of TIPS in portal thrombosis</b> FOR: Virginia Hernández, MD (SPAIN)   AGAINST: Brett Fortune, MD (USA)		<b>Serum ammonium levels: useful biomarker in decompensated liver cirrhosis</b> FOR: Edgar Santino, MD (MEXICO)   AGAINST: Juan Turnes, MD (SPAIN)
15:10–15:30	<b>Lifelong immunosuppression in autoimmune hepatitis</b> FOR: Lorena Castro, MD (CHILE)   AGAINST: Eira Cerda, MD (MEXICO)		<b>Other indications for the use of albumin in cirrhosis</b> FOR: Angelo Mattos, MD (BRAZIL)   AGAINST: Aldo Torre, MD (MEXICO)
15:30–15:45	<b>Q&amp;A</b> Brian Lee, MD (USA) · Gabriel Mezzano, MD (CHILE)		<b>Q&amp;A</b> Nicolás Fernández, MD (MEXICO) · Kriss del Rocío Rodríguez, MD (PERU)
15:45–16:15 COFFEE BREAK			
16:15–19:00 ROOM A Premiation and Closure			
16:15–16:35	<b>Movements that make a difference: experiences at the closure of ALEH 2024</b> Javier Brahm, MD (CHILE)		
16:35–16:55	<b>Towards global recognition of the MASLD/MASH public health threat</b> Jeffrey Lazarus, MD (ESPAÑA)		
16:55–17:25	<b>Round Table: Healthy Liver Healthy Lives</b>   COORDINATOR: JEFFREY LAZARUS, MD (SPAIN) Grace Su, MD (AASLD) · Aleksander Krag, MD (EASL) · Lai Wei, MD (APASL) · Mario Pessoa, MD (ALEH) · Zobair Younossi, MD (GNC)		
17:25–17:40	<b>OP-1 Simultaneous liver-kidney transplantation outcomes in Latin America</b> Jorge Carlos Martínez Morales, MD (ARGENTINA)		
17:40–17:55	<b>OP-2 Characterization of Steatotic Liver Disease and the role of genetic background in Latin America</b> Luis Díaz Piga, MD (CHILE)		
17:55–18:10	<b>OP-3 Recompensation in patients with cirrhosis prior to first line systemic therapy is associated with similar survival outcomes compared to compensated cirrhosis</b> Federico Piñero, MD (ARGENTINA)		
18:10–18:20	<b>Latin American Hepatologist Award</b>		
18:20–18:30	<b>International Hepatologist Award</b>		
18:30–19:00	<b>President's Report / Change of President</b>		



SPONSORS



SISTER SOCIETIES



CONGRESS 2024  
SANTIAGO - CHILE 

SEPTEMBER 9<sup>th</sup>-11<sup>th</sup>

THANKS TO

Abbvie · Medix · Alfasigma

[www.congresoaleh.com](http://www.congresoaleh.com)